An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 30, 2017

Study Completion Date

May 16, 2022

Conditions
Choroideremia
Interventions
GENETIC

rAAV2.REP1 vector

No additional details needed.

Trial Locations (1)

T6G 2E1

University of Alberta, Edmonton

Sponsors
All Listed Sponsors
collaborator

Alberta Innovates Health Solutions

OTHER

collaborator

Canada Foundation for Innovation

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Choroideremia Research Foundation Canada

UNKNOWN

collaborator

Foundation Fighting Blindness

OTHER

collaborator

Imperial College London

OTHER

collaborator

University of Oxford

OTHER

lead

University of Alberta

OTHER